$SUPN (Supernus Pharmaceuticals, Inc.)

$SUPN {{ '2016-10-11T12:46:51+0000' | timeago}} • Announcement

$SUPN announced positive topline results from its Phase IIb clinical trial of SPN-812, a drug for the treatment of attention deficit hyperactivity disorder (ADHD) in children. The trial succeeded in meeting the primary endpoint. The company plans for an end-of-Phase II meeting with the U.S. FDA and then it will start the Phase III clinical testing.

$SUPN {{ '2017-09-18T20:39:00+0000' | timeago}} • Announcement

$SUPN provided update on SPN-810 phase 3 clinical trials. Based on the predefined criteria for dropping a dose arm, the lower dose of 18 mg will be eliminated. $SUPN said this will maximize probability of reaching statistically significant outcome for the 36 mg dose, which will start immediately. $SUPN still expects enrollment through mid-2018.

$SUPN {{ '2017-09-18T20:37:20+0000' | timeago}} • Announcement

$SUPN provided update on SPN-810 phase 3 clinical trials. The company is developing SPN-810 as a novel treatment for impulsive aggression (IA) in patients aged 6 to 12 years who have attention deficit hyperactivity disorder (ADHD). The interim analysis has been completed and both trials will continue through to completion.

$COO {{ '2017-09-11T20:51:49+0000' | timeago}} • Announcement

Medical devices company $COO has signed an agreement with pharma firm $TEVA to acquire the global rights and business of Teva’s Paragard Intrauterine Device for $1.1Bil in cash. The transaction, which is likely to close prior to the end of the calendar year, is expected to be accretive to Cooper's earnings by $0.7-0.75 per share in the first year.

$TEVA {{ '2017-09-11T20:47:29+0000' | timeago}} • Announcement

Israeli drugmaker $TEVA appointed Kare Schultz as its CEO replacing the current acting CEO Yitzhak Peterburg, who will continue as acting CEO until Schultz joins. Schultz, who will move to Israel and be based at Teva's headquarters, recently served as CEO of Denmark-based H. Lundbeck A/S. Prior to this job, he held the post of COO in Novo Nordisk.

$SUPN {{ '2017-08-15T21:18:52+0000' | timeago}} • Announcement

$SUPN said the US District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. infringed $SUPN’s patents by submitting to the FDA an ANDA seeking permission to market a generic version of Oxtellar XR before the expiration of $SUPN’s patents. The Court also confirmed the validity of $SUPN’s patents.

$AGN {{ '2017-08-03T18:43:48+0000' | timeago}} • Announcement

$AGN, which owns 9.9% stake in $TEVA, reported a wider loss in 2Q17, hurt by the loss of patent exclusivity and lower revenues from certain drugs. Net loss attributable to ordinary shareholders was $796MM or $2.37 per share compared to $571MM or $1.44 per share a year ago. However, revenue rose 9% to $4.01Bil and adjusted EPS increased 20% to $4.02.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$DEPO {{ '2017-07-13T12:48:44+0000' | timeago}} • Announcement

Pharma company $DEPO is seeking to refinance its existing $375MM principal amount of privately placed secured senior notes. The notes are due in 2022. The terms of refinancing are subject to various factors, including satisfaction of customary closing conditions.

$SUPN {{ '2017-06-21T16:52:36+0000' | timeago}} • Announcement

$SUPN said the FDA has approved Mydayis, a once-daily treatment for patients with Attention Deficit Hyperactivity Disorder. Mydayis is not for use in children 12 years and younger. The treatment will be commercially available in the US in 3Q17.

$PBH {{ '2017-05-11T19:07:14+0000' | timeago}} • Webcast

$PBH stated that it saw $19MM of targeted Fleet run-rate synergies, of which $16MM will flow though SG&A and $3MM would flow though COG. It expects a majority of the SG&A synergy realizations to be completed by 1Q18, while that from COG is expected to take longer.

$PBH {{ '2017-05-11T18:51:43+0000' | timeago}} • Webcast

$PBH stated that it hopes to see more growth in the first half of FY18 than the second half, primarily due to the carry over from 4Q17.

$TEVA {{ '2017-05-11T14:45:27+0000' | timeago}} • Webcast

$TEVA stated that with regards to generics, it is looking at a combination of both revenue and margins. On revenue, it's a combination of what's happening in its base business in the US. Additionally, for rest of the year, $TEVA expects the current levels of price erosion and on product launch it continues to look at the 40-50 launch opportunity.

$TEVA {{ '2017-05-11T14:16:58+0000' | timeago}} • Webcast

$TEVA said that regarding the US new product launches, the company is targeting more than 80 different product opportunities that are expected to yield between 40-50 launches in 2017. Looking at the breakdown, the products with high level of confidence are expected to generate approx. $500MM.

$TEVA {{ '2017-05-11T14:06:03+0000' | timeago}} • Webcast

$TEVA reduced its headcount by approx. 5,000 people since the close of the Actavis Generics transaction and expects further reductions through the end of 2017. Additionally, the company reduced its gross debt by $1.2Bil from $35.8Bil at the end of 2016 to $34.6Bil at the end of 1Q17.

$TEVA {{ '2017-05-11T13:58:08+0000' | timeago}} • Infographic

$TEVA Teva Pharmaceutical Industries Limited Earnings AlphaGraphics: Q1 2017 highlights

$TEVA {{ '2017-05-11T11:28:43+0000' | timeago}} • Announcement

Generic medicines revenues for $TEVA in 1Q17 soared 24% to $3.1Bil, while those from specialty medicines slid 6% to $2.0Bil. "We now expect to realize cumulative net synergies and cost reduction of approximately $1.5 billion by the end of 2017," said Dr. Yitzhak Peterburg, interim CEO.

$TEVA {{ '2017-05-11T11:24:32+0000' | timeago}} • Announcement

Revenues for $TEVA in 1Q17 were up 17% at $5.6Bil, as the Israel-based pharma company posted a slight rise in net attributable income to $580MM from last year's $570MM. Earnings were $0.57 per diluted share vs. $0.62 a share, with R&D expenses spiking 17% to $457MM for the quarter.

$PBH {{ '2017-05-11T10:36:42+0000' | timeago}} • Announcement

$PBH's BoD elected Ron Lombardi as Chairman of the Board. Gary Costley will remain the company's Lead Independent Director. The Board is confident Lombardi will provide outstanding leadership as Chairman, President and CEO in the coming years.

$PBH {{ '2017-05-11T10:33:29+0000' | timeago}} • Announcement

$PBH expects FY18 revenue growth of 18-20%, adjusted EPS of $2.58-2.68 and adjusted free cash flow of $205MM or more. The company plans to continue using its industry-leading free cash flow to pay down debt and build M&A capacity.

Recent Transcripts

NVO (Novo Nordisk A/S)
Thursday, August 10 2017 - 12:15pm
NVO (Novo Nordisk A/S)
Wednesday, August 9 2017 - 11:00am
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SUPN (Supernus Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 1:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, May 11 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
SUPN (Supernus Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 1:00pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
NVO (Novo Nordisk A/S)
Thursday, May 4 2017 - 12:15pm

AlphaGraphics you may like